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Abstract Read-through fusion transcripts that result from
the splicing of two adjacent genes in the same coding
orientation are a recently discovered type of chimeric
RNA. We sought to determine if read-through fusion
transcripts exist in breast cancer. We performed paired-end
RNA-seq of 168 breast samples, including 28 breast cancer
cell lines, 42 triple negative breast cancer primary tumors,
42 estrogen receptor positive (ER?) breast cancer primary
tumors, and 56 non-malignant breast tissue samples. We
analyzed the sequencing data to identify breast cancer
associated read-through fusion transcripts. We discovered
two recurrent read-through fusion transcripts that were
identified in breast cancer cell lines, confirmed across
breast cancer primary tumors, and were not detected in
normal tissues (SCNN1A-TNFRSF1A and CTSD-
IFITM10). Both fusion transcripts use canonical splice sites
to join the last splice donor of the 50 gene to the first splice
acceptor of the 30 gene, creating an in-frame fusion tran-
script. Western blots indicated that the fusion transcripts
are translated into fusion proteins in breast cancer cells.
Custom small interfering RNAs targeting the CTSD-
IFITM10 fusion junction reduced expression of the fusion
transcript and reduced breast cancer cell proliferation.
Read-through fusion transcripts between adjacent genes
with different biochemical functions represent a new type
of recurrent molecular defect in breast cancer that warrant
further investigation as potential biomarkers and thera-
peutic targets. Both breast cancer associated fusion tran-
scripts identified in this study involve membrane proteins
(SCNN1A-TNFRSF1A and CTSD-IFITM10), which raises
the possibility that they could be breast cancer-specific cell
surface markers.
Introduction
Fusion genes with oncogenic activity were first identified
in hematologic malignancies, where chromosomal trans-
locations frequently join two genes that result in an aber-
rant protein product [1, 2]. These fused genes have been
valuable prognostic markers and therapeutic targets [3].
The therapeutic value of identifying fusion genes is
exemplified by the development of selective inhibitors
targeted to the ABL kinase involved in the BCR–ABL
fusion that is present in 95 % of patients with chronic
myelogenous leukemia [1, 2, 4]. Most recurrent fusion
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genes have been identified in leukemias, lymphomas, and
soft tissue sarcomas where cytogenetic approaches to
detect chromosomal aberrations using spectral karyotyp-
ing, fluorescent in situ hybridization, and flow cytometry
have been developed [5]. Cytogenetic approaches to detect
fusion genes in the more common forms of cancer, epi-
thelial tumors, are hampered by the poor chromosome
morphology, complex karyotypes, and cellular heteroge-
neity that typify these tumors, although it has been posited
that fusion genes are likely drivers of oncogenesis in these
tumors as well [3, 5, 6]. Until recently, the most prevalent
recurrent fusion genes identified in breast cancer were the
ETV6-NTRK3 fusion in secretory breast carcinoma, a rare
subtype of infiltrating ductal carcinoma [7] and the MYB-
NFIB fusion in adenoid cystic carcinomas, another rare
form of breast cancer [8]. Recently, genome-wide micro-
array profiling, the whole genome sequencing and the
whole transcriptome sequencing have made it possible to
systematically identify fusion genes in solid tumors. With
these methods, recurrent fusions that contribute to malig-
nancy have been identified in prostate cancer (e.g.,
TMPRSS2 fused to ETS family transcription factors [9–
11]), in lung cancer (EML4–ALK [12]), and in breast
cancer (MAST kinases fused to NOTCH family genes
[13]). New technologies and informatics approaches are
enabling the identification of recurrent fusion genes in
more common epithelial cancers that may serve as valuable
biomarkers and drug targets [13–19].
In addition to fusion genes created by genomic rear-
rangements, fusion transcripts created by cis- and trans-
splicing of mRNA, in the absence of a DNA rearrange-
ments, have been detected by sequencing cDNA clone
libraries and performing RNA-seq [20]. These chimeric
RNAs have been detected at low levels in expressed
sequence tag (EST) libraries [21–23] and low levels across
benign and malignant samples [6, 20, 24]. One particularly
prevalent class of chimeric RNAs involves adjacent genes
in the same coding orientation that are spliced together to
form an in-frame chimeric transcript that spans both genes.
In the recent literature, these have been referred to as read-
through gene fusions, transcription-induced chimeras, co-
transcription of adjacent genes coupled with intergenic
splicing (CoTIS), or conjoined genes. Several of these
read-through fusion transcripts have been identified spe-
cifically in prostate cancer and are associated with cellular
proliferation and disease progression [25–33]. Recurrent
read-through transcripts have not yet been characterized in
breast cancer. We used paired-end RNA-seq to identify two
novel recurrent read-through fusion transcripts associated
with breast cancer, and we used genomic DNA sequencing,
qPCR, cDNA clone sequencing, small interfering RNA
(siRNA) knockdown, and Western blots to further confirm
and characterize these fusion transcripts.
Results
Identification of read-through fusion transcripts
in breast cancer cell lines
While recent studies have reported recurrent fusion genes
in breast cancer that are the result of genomic rearrange-
ments [13, 15, 16, 18, 34], recurrent read-through fusion
transcripts in breast cancer have not been previously
characterized. We performed RNA-seq [35] on 28 breast
cancer cell lines to identify candidate read-through fusion
transcripts. We used the ChimeraScan software package to
identify read-through transcripts in the RNA-seq data [36].
There were 6 candidate read-through fusion transcripts that
were supported by at least 10 read pairs that connect
adjacent genes and at least one sequencing read that
spanned the fusion junction in more than two breast cancer
cell lines (SIDT2-TAGLN, CTBS-GNG5, CLTC-VMP1,
MFGE8-HAPLN3, SCNN1A-TNFRSF1A, CTSD-IFITM10;
Table1).
Confirmation of candidate fusion transcripts in primary
breast tumors
To determine if the read-through fusion transcripts detected
in breast cancer cell lines were present in primary breast
tumors, we performed RNA-seq [35] on 42 fresh frozen triple
negative breast cancer (TNBC) primary tumors and 42 fresh
frozen estrogen receptor positive (ER?) breast cancer pri-
mary tumors. We again used the ChimeraScan software
package to identify read-through transcripts in the RNA-seq
data [36]. Five of the candidate fusion transcripts were
detected with at least one fusion junction-spanning read in
the primary tumors (SIDT2-TAGLN, CTBS-GNG5, MFGE8-
HAPLN3, SCNN1A-TNFRSF1A, CTSD-IFITM10; Table 1).
Tumor specificity of fusion transcripts
To determine if the read-through fusion transcripts were
associated with breast cancer, or whether they were present
in normal tissues, we then performed RNA-seq [35] on 21
uninvolved breast tissue samples that were adjacent to
TNBC tumors, 30 uninvolved breast tissue samples that
were near ER? breast tumors, and five normal breast tissue
samples that were collected from cancer-free patients
during reduction mammoplasty procedures. We also ana-
lyzed RNA-seq data from 13 normal human tissues col-
lected by the Illumina Human Body Map 2.0 project,
which includes adipose, brain, breast, colon, heart, kidney,
liver, ovary, prostate, skeletal muscle, testes, thyroid, and
white blood cells [15]. We again used the ChimeraScan
software package to identify read-through transcripts in the
RNA-seq data [36]. The SIDT2-TAGLN and CTBS-GNG5
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fusion transcripts were detected at a high frequency in a
variety of normal tissues (Table 1).
The remaining three fusion transcripts we detected
exclusively in breast tumor and normal tissue are MFGE8-
HAPLN3, SCNN1A-TNFRSF1A and CTSD-IFITM10. We
used Fisher’s Exact test to determine if the read-through
fusion transcripts were significantly overrepresented in the
breast cancer samples compared to the non-cancer breast
samples. We found that SCNN1A-TNFRSF1A and CTSD-
IFITM10 were significantly associated with breast cancer
(p \ 0.05; Table 1). The fusion junction-spanning reads
for these read-through fusion transcripts are depicted in
Fig. 1, and the number of fusion junction-spanning reads in
each sample is reported in Supplemental Table 1. These
fusions were present in both ER? breast cancer and TNBC,
and they are frequent events. In our cohorts the breast
cancer associated fusion transcripts were detected in 46 %
(13/28) of the breast cancer cell lines, 29 % (12/42) of the
TNBC primary tumors, and 19 % (8/42) of the ER? breast
cancer primary tumors.
The CTSD-IFITM10 fusion transcript was not detected
in any normal tissue RNA-seq data. To determine if the
Fig. 1 Breast cancer associated read-through fusion transcripts. Two
breast cancer associated read-through fusion transcripts, SCNN1A-
TNFRSF1A (a) and CTSD-IFITM10 (b), were detected in paired-end
RNA-seq performed on breast cancer cell lines and primary tumors
and were not detected in a variety of non-neoplastic human tissues.
The 50 gene partner is depicted in green, and the 30 gene partner is
depicted in red. The fusion transcripts use endogenous splice sites to
fuse the two transcripts and the angled black lines indicate which
exons flank the fusion junction to result in the chimeric transcript.
RNA-seq reads that span the fusion junction are depicted above the
gene models and the sequence from the 50 partner is in green text and
the sequence from the 30 partner is in red text. The intergenic
chromosomal distance between the fusion partners is denoted in
kilobase pairs (kbp). Breast cancer cell line cDNA was PCR amplified
using primers in the distal ends of the partner genes, and clones were
sequenced. The alignment of the cDNA to the genome and the
canonical gene models at this locus are depicted for SCNN1A-
TNFRSF1A (c) and CTSD-IFITM10 (d). Both fusion transcripts
include all of the canonical exons and splice sites of the partner genes
up to the fusion junction and the fusion junction maintains the reading
frame of the canonical transcripts









































SIDT2-TAGLN 13 (46 %) 18 (43 %) 20 (48 %) 21 (100 %) 28 (93 %) 5 (100 %) 9 (69 %) a
CTBS-GNG5 13 (46 %) 24 (57 %) 21 (50 %) 19 (90 %) 25 (83 %) 5(100 %) 10 (77 %) a
CLTC-VMP1 2 (7 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0.3816
MFGE8-HAPLN3 4 (14 %) 23 (55 %) 4 (10 %) 4 (19 %) 7 (23 %) 1 (20 %) 0 (0 %) 0.0794
SCNN1A-TNFRSF1A 10 (36 %) 3 (7 %) 5 (12 %) 1 (5 %) 1 (3 %) 0 (0 %) 0 (0 %) 0.0039
CTSD-IFITM10 7 (25 %) 9 (21 %) 5 (12 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) \0.0001
For each fusion transcript the number of samples containing junction-spanning reads is listed. Read-through fusion transcripts that are signif-
icantly associated with breast cancer are given in bold and p values are listed in the last column
a More prevalent in non-cancer samples
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CTSD-IFITM10 fusion is transcribed in normal tissue
below the level of detection of RNA-seq, we performed
qPCR using primers that flank the fusion junction (Fig. 4a)
in 9 normal breast tissue samples including 3 non-malig-
nant tissues samples adjacent to TNBC tumors, 2 non-
malignant tissues adjacent to ER? tumors, and 4 normal
breast tissue samples from reduction mammoplasty pro-
cedures. The expression of the fusion transcript in normal
samples was compared to the expression of the fusion
transcript in MDA-MB-468, a cell line in which 9 fusion
junction-spanning reads were detected by RNA-seq. The
fusion transcript expression measurements in the normal
samples were near the limit of detection of our qPCR
assay, and were an average of 84 fold lower than the
expression in the positive control cell line (Supplemental
Fig. 1). These results are consistent with the lack of
expression observed in the normal tissue RNA-seq data.
Structure and expression of read-through fusion
messages
To determine which exons are included in the breast cancer
associated fusion transcripts, we PCR amplified the fusion
transcript from breast cancer cell line cDNA using forward
primers in the 50 gene exons and reverse primers in the 30
gene exons. We then cloned and sanger sequenced the PCR
products from the most distal primers to determine the full
coding sequence of the fusion transcripts. Both SCNN1A-
TNFRSF1A and CTSD-IFITM10 included all canonical
exons and splice sites of the partner genes up to the fusion
junction, and the coding sequence is in-frame across the
fusion junction (Fig. 1).
For the read-through fusion mRNA to be transcribed,
RNA polymerase would begin in the promoter of the 50
gene, continue across the intergenic region and terminate
after the 30 UTR of the 30 gene. This is possible for these
fusion transcripts, because the intergenic region between
the genes is small for both loci (4.8 kbp between SCNN1A
and TNFRSF1A, and 2.2 kbp between CTSD and
IFITM10). Additionally, the genomic distance from the
start of the 50 gene partner to the end of 30 gene partner is
less than the average genomic distance traversed by RNA
polymerase II for canonical genes in the human genome
(48 kbp for SCNN1A-TNFRSF1A, 31 kbp for CTSD-
IFITM10, 56 kbp for average gene length in human
genome).
Both fusion transcripts use canonical splice sites to join
the last splice donor of the 50 gene to the first splice acceptor
of the 30 gene. This splicing pattern skips the last exon of the
50 gene and the first exon of the 30 gene (Fig. 1). In order for
this product to form, the 50 gene’s terminal exon splice
acceptor site has been skipped, which results in the usage of
the next available splice acceptor residing in the adjacent 30
gene. To determine whether a mutation or a deletion at the
50 gene’s terminal exon is associated with the formation of
these read-through fusion transcripts, we sequenced 200 bp
of genomic DNA surrounding the skipped splice acceptor
site. We did not identify any mutations associated with the
presence of the fusion transcripts and we observed both
alleles of heterozygous SNPs at expected frequencies.
These results indicate that neither fusion transcript is
associated with genomic DNA mutations or deletions of the
skipped last exon of the 50 gene.
An alternative hypothesis is that the kinetics of tran-
scription at these loci are skewed to favor inter-gene splicing
of the read-through fusion transcript before canonical
splicing and 30 cleavage of the upstream gene occurs. We
calculated the fraction of reads near the fusion junction that
include sequence from the fusion transcript rather than the
un-fused canonical transcripts. This fraction reflects the
abundance of the chimeric transcript relative to the canonical
isoform (Fig. 2a). Only a small fraction of the transcripts
from the 50 gene include the fusion, and a significantly higher
fraction of transcripts from the 30 gene are fusion transcripts
(Mann–Whitney test: SCNN1A vs TNFRSF1A p = 0.0247,
and CTSD vs IFITM10 p \ 0.0001). This indicates that a
larger proportion of the transcription of the 30 partner is
created from read-through transcripts beginning at the 50
gene promoter. Higher expression of the 50 gene could lead to
run-on transcription into the adjacent 30 gene. We examined
the expression of the 50 fusion partner gene but found that
there was no difference in expression levels between samples
with and without the fusion. This indicates that the steady
state expression level of the 50 gene is not associated with the
presence of these fusions (Fig. 2b). In summary, these breast
cancer associated read-through fusion transcripts, which
account for a significant portion of the 30 gene’s expression,
are independent of the 50 gene’s expression level.
Detection of fusion proteins
Both of the breast cancer associated read-through fusion
transcripts we identified involved genes that encode mem-
brane proteins. These proteins’ functions rely on their correct
placement in the membrane and correct participation in pro-
tein complexes. SCNN1A is an alpha subunit of nonvoltage-
gated, amiloride-sensitive, sodium channels [37]. It is fused to
TNFRSF1A, a tumor necrosis factor-alpha receptor that
activates NF-jB, mediates apoptosis, and regulates inflam-
matory responses [38]. CTSD is a lysosomal aspartyl protease
that also functions as a secreted protein that binds membrane
receptors and has previously been associated with breast
cancer [39]. It is fused to IFITM10, a member of a family of
membrane proteins that are induced by interferon and are
involved in cell proliferation and cell adhesion [40]. These
read-through fusion transcripts join genes that have disparate
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functions, suggesting that a fused protein could impair normal
function or localization in breast cancer.
We predicted the length of the fusion protein based upon
the fusion transcript sequence, and used Western blots with
an antibody raised against one of the native partner proteins
to determine whether a protein of the predicted fusion size
could be detected in cell lysates from cell lines with and
without RNA transcript evidence of the fusion. We
observed specific Western blots of the targeted protein at
the expected canonical size and detected protein at the
predicted fusion size specifically in the cell lines with the
fusion transcripts, and not in cell lines without the fusions
for both of the breast cancer associated read-through fusion
transcripts (Fig. 3). The cell line with the most fusion-
spanning reads was positive for the fusion in both Western
blots, and in the case of the SCNN1A-TNFRSF1A, the cell
line with the second highest number of fusion-spanning
reads, was also positive by Western blot. These results
suggest that the breast cancer associated read-through
fusion transcripts are translated into fusion proteins. This
observation raises the possibility that these cancer-specific
fusion proteins may be expressed on the membrane of
breast cancer cells and warrants further investigation as
potential cell surface antibody drug targets.
Fusion transcript associated with proliferation
The CTSD-IFITM10 fusion transcript appears to be breast
cancer specific, i.e., it was detected exclusively in breast
cancer samples and not detected in any normal tissues. It
was also detected in RNA-seq data from the MCF7 breast
cancer cell line, which makes it amenable to further
investigation in vitro. We designed two custom siRNA
duplexes to target the fusion junction of the read-through
fusion transcript (Fig. 4a). We transfected the MCF7 cell
line with the siRNA duplexes targeting the fusion transcript
and measured the abundance of fusion transcript 48 h after
transfection using quantitative PCR (qPCR) with primers
flanking the fusion junction (Fig. 4a). Both siRNAs tar-
geting the fusion junction of CTSD-IFITM10 produced
knockdown of the fusion transcript resulting in 42–51 % of
the transcript remaining relative to treatment with a non-
targeting siRNA (Fig. 4b). To determine if knockdown of
the fusion transcript affects cell proliferation, we measured
Fig. 2 Expression of genes involved in breast cancer associated read-
through fusion transcripts. a We computed the fraction of reads that
include sequence from the fusion transcript rather than the un-fused
canonical transcript. The fraction of fusion transcript reads for 50
fusion partners are indicated in green, and the 30 fusion partners are
denoted in red for each of the samples. Mean and standard error of the
mean are depicted in black. Less than 20 % of the 50 fusion partners’
transcripts include the fusion sequence, indicating that most of the
transcripts from the 50 gene are not fused. A significantly larger
fraction of the 30 gene’s transcripts contain the fusion sequence
(Mann–Whitney test: SCNN1A vs TNFRSF1A p = 0.0247, and CTSD
vs IFITM10 p \ 0.0001). b There is not a significant difference in the
expression levels of the 50 fusion partner between samples with or
without the read-through fusion transcript (labeled fused and not
fused, respectively). This indicates that increased expression of the 50
fusion partner is not sufficient to induce read-through fusion
transcripts that include the 30 gene
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the number of live cells 72 h after transfection with each
siRNA targeting the fusion junction. We found that both
siRNAs targeting the CTSD-IFITM10 fusion transcript
resulted in a significant decrease in the number of live cells
(p \ 0.03) resulting in 10–17 % reduction in live cell
numbers compared to treatment with the non-targeting
siRNA (Fig. 4c). While this decrease is modest, it is
important to note that this cell phenotype is evident even
when 45 % of the fusion transcript remains after
knockdown. This qPCR detection and siRNA knockdown
further confirm the presence of the CTSD-IFITM10 read-
through fusion transcript and indicate that its abundance is
associated with MCF7 breast cancer cell proliferation.
Discussion
To our knowledge, this is the first report characterizing
recurrent read-through fusion transcripts associated with
breast cancer. Significant effort has been devoted to iden-
tifying gene expression differences and DNA mutations in
breast cancer, and this report adds aberrant mRNA read-
through fusion transcripts to the list of molecular defects
associated with the disease. Both recurrent fusion tran-
scripts associated with breast cancer involved membrane
proteins, which raises the exciting possibility that they are
breast cancer-specific cell surface markers that could be
targeted with antibody–drug conjugates. In the MCF7
breast cancer cell line, the siRNA knockdown of CTSD-
IFITM10 fusion was associated with a decrease in live cells
suggesting this fusion plays a role in breast cancer cell
proliferation. Read-through fusion transcripts represent a
new class of exciting candidate biomarkers and potential
therapeutic targets for further investigation in breast can-
cer. Future work to elucidate the mechanisms leading to the
read-through transcription, mis-splicing, and loss of poly-
adenylation that create these fusions is also warranted to
determine whether a defect in the regulation of these pro-
cesses is responsible for these aberrant transcripts.
Materials and methods
Cell lines and tissues
De-identified fresh frozen breast cancer specimens, fresh
frozen matched uninvolved breast tissue adjacent to tumors,
and fresh frozen breast tissue specimens from reduction
mammoplasty procedures were obtained from the University
of Alabama at Birmingham’s Comprehensive Cancer Center
Tissue Procurement Shared Facility. The specific aliquots of
specimens provided for research were chosen based on their
quality control by board certified pathologists. After identifi-
cation by quality control, the uninvolved breast tissue aliquots
were not further macro-dissected. The breast tumor specimens
were macro-dissected by the pathologists at the Tissue Pro-
curement Shared Facility to enrich for tumor cell content and
remove adjacent normal tissue. The frozen breast tissue
specimens were weighed, transferred to a 15 mL conical tube
containing ceramic beads, and RLT Buffer (Qiagen) plus 1 %
BME was added so that the tube contained 35 lL of buffer for
each milligram of tissue. The conical tubes containing tissue,
Fig. 3 Western blots of breast cancer associated fusion proteins. We
performed Western blots using antibodies raised to one of the fusion
partner proteins for the breast cancer associated fusion transcripts. For
each candidate fusion, we ran cell lysates from two cell lines with
RNA-seq reads spanning the fusion junction and one cell line without
RNA-seq reads spanning the fusion junction. In each blot, the
canonical/native size of the targeted protein was detected in each cell
line, and a band at the predicted fusion protein size was detected in
the cell line with the most RNA-seq fusion-spanning reads (CTSD-
IFITM10 in MCF-7, and SCNN1A-TNFRSF1A in HCC1954). A
band corresponding to the size of the predicted fusion protein was
also detected in the cell line with the second most RNA-seq fusion
transcript reads for the SCNN1A-TNFRSF1A fusion (SUM-102).
None of the cell lines without RNA-seq evidence of the fusion
transcript produced fusion protein-sized bands
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ceramic beads and buffer were then shaken in a MP Bio-
medicals FastPrep machine until the tissue was visibly
homogenized (90 s at 6.5 meters per second). The homoge-
nized tissue was stored at -80 C. The 28 breast cancer cell
lines were cultured as described previously [41].
RNA-seq
Total RNA was extracted from 5 million cultured cells or
350 lL of tissue homogenate (equivalent to 10 mg of tis-
sue) using the Norgen Animal Tissue RNA Purification Kit
(Norgen Biotek Corporation). Cell lysate was treated with
Proteinase K before it was applied to the column, and on-
column DNAse treatment was performed according to the
manufacturer’s instructions. Total RNA was eluted from
the columns and quantified using the Qubit RNA Assay Kit
and the Qubit 2.0 fluorometer (Invitrogen). RNA-seq
libraries for each sample were constructed from 250 ng
total RNA using the polyA selection and transposase-based
non-stranded library construction (Tn-RNA-seq) described
previously [35]. RNA-seq libraries were barcoded during
PCR using Nextera barcoded primers according to the
manufacturer (Epicentre). The RNA-seq libraries were
quantified using the Qubit dsDNA HS Assay Kit and the
Qubit 2.0 fluorometer (Invitrogen), and three barcoded
libraries were pooled in equimolar quantities for sequenc-
ing. The pooled libraries were sequenced on an Illumina
HiSeq 2000 sequencing machine using paired-end 50 bp
Fig. 4 CTSD-IFITM10 read-through fusion transcript siRNA knock-
down. a We designed qPCR primers to flank the fusion junction of the
CTSD-IFITM10 read-through fusion transcript and we designed two
custom siRNAs to target the fusion junction. The sequence from the
CTSD (the 50 gene) is indicated in green and the sequence from
IFITM10 (30 gene) is indicated in red. The MCF7 breast cancer cell
line was transfected with two siRNAs targeting the CTSD-IFITM10
fusion junction. b qPCR of the fusion transcript was performed 48 h
after transfection. Both siRNAs significantly reduced the abundance
of the fusion transcript relative to the controls, which included a non-
targeting siRNA and a mock transfection that did not contain any
siRNA. c A quantitative cell proliferation assay was performed 72 h
after transfection. Both siRNAs significantly reduced the number of
live cells relative to the controls
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reads and a 6 bp index read, and we obtained at least 50
million read pairs from each library. ChimeraScan 0.4.5a
was used to align reads to the hg19 human reference
genome and utilize the UCSC Known Gene annotation file
to identify fusion transcripts in each of the sequencing
libraries [36]. ChimeraScan 0.4.5a default parameters were
used, including using the bowtie -best -strata option for
alignment, 2 mismatches tolerated at breakpoints, 4 bp
minimum overlap required to call spanning reads, 8 bp
anchor region where mismatch checks are enforced, and 0
mismatches allowed within the anchor region. Default fil-
ters include removing chimeras with less than 2 unique
aligned fragments, removing chimeras when the probabil-
ity of observing the putative insert size is than 0.01, or
when the expression ratio relative to the wild-type tran-
scripts is less than 0.01. To quantify the expression of each
fusion partner gene, we used TopHat v1.4.1 [42] with the
options -r 100 -mate-std-dev 75 to align 50 million RNA-
seq read pairs, and used GENCODE version 9 [43] as a
transcript reference. Gene expression values (fragments per
kilobase of transcript per million reads, FPKMs) were
calculated for each GENCODE transcript using Cufflinks
1.3.0 with the -u option [44].
Fusion transcript cDNA cloning and Sanger sequencing
Total RNA from the MCF-7 and HCC1954 breast cancer cell
lines was extracted using the Norgen Animal Tissue RNA
Purification Kit (Norgen Biotek Corporation). First strand
cDNA was prepared from total RNA using Dynabeads oli-
go(dT) (Invitrogen) to select polyadenylated mRNA and
SuperScript II Reverse Transcriptase with Random Hexa-
mers (Invitrogen). PCR primers were designed to each exon
in the fusion partner genes and used to amplify the SCNN1A-
TNFRSF1A fusion transcript from HCC1954 and the CTSD-
IFITM10 fusion transcript from MCF-7. PCR was performed
using 0.5 lM each primer, 1 lL cDNA, 19 Phusion High-
Fidelity PCR Master Mix with HF Buffer (New England
Biolabs), and 3 % DMSO. The largest PCR products were





PCR products were extracted from agarose gels using the
Qiagen Qiaquick Gel Extraction Kit and A-tailing was per-
formed using 2.5 U Klenow Fragment (30 ? 50 exo-) (New
England Biolabs) and 450 lM dATP in a 55-lL reaction
containing 19 NEBuffer 2 (New England Biolabs). The PCR
products were ligated into the pGEMT Easy vector (Pro-
mega) and transformed into JM109 High Efficiency Com-
petent Cells (Promega). Blue white screening was used to
select transformed clones for overnight liquid culture and
plasmid preparation using Wizard Plus SV Miniprep DNA
Purification System (Promega). Plasmids were sequenced
from both ends of the PCR product insert using M13 pUC
Forward and Reverse primers on ABI 3730XL sequencers by
MC Lab (San Francisco, CA).
Splice junction DNA sequencing
Genomic DNA was isolated from 12 breast cancer cell
lines using 5 million cultured cells per cell line and the
Qiagen DNeasy Kit. PCR amplification of 200 bp sur-
rounding the terminal exon splice acceptor site that is
skipped in the formation of the read-through fusion tran-
scripts were performed in 50 lL reactions containing 5 ng
genomic DNA, 0.5 lM Forward PCR primer, 0.5 lM
Reverse PCR primer, 5 units Platinum Taq DNA Poly-
merase (Invitrogen), 19 PCR Buffer with 2 mM MgCl2,
0.5 mM each dNTP, and 0.5 M Betaine. These reactions
were denatured at 98 C for 1 min then thermocycled (30
cycles of 95 C for 30 s and 62 C for 3 min) and held at
4 C. The PCR products were purified using Agencourt
AMPure XP beads (Beckman Coulter). The PCR products
were quantified using the Qubit dsDNA HS Assay Kit and
the Qubit 2.0 fluorometer (Invitrogen). Equimolar quanti-
ties of each of the eight PCR products were pooled into 12
pools, one for each cell line. Illumina sequencing libraries
were prepared for each of the 12 pools of PCR products
using Nextera according to the manufacturer’s instructions
(Epicentre). The 12 libraries were quantified using the
Qubit dsDNA HS Assay Kit and the Qubit 2.0 fluorometer
(Invitrogen). Equimolar quantities of each library were
pooled and diluted to 10 nM and sequenced using single-
end 50 bp reads and a 6 base index read on the Illumina
MiSeq sequencer. We obtained 6 million sequencing reads
in total covering all 8 amplicons in each of the 12 breast
cancer cell lines. Variants were identified by the GATK
software on BaseSpace (Illumina), and BAM files were
downloaded and inspected manually using IGV 2.0 [45].
Western blots
Breast cancer cell pellets containing 2.5 million cells were
lysed by adding 100 lL RIPA Buffer (19 PBS, 1 % NP-
40, 0.5 % sodium deoxycholate, 0.1 % SDS, and Roche
protease inhibitor cocktail) and passing the solution
through a 21-gauge needle. The lysed cells were then
centrifuged at 16,000 rcf for 15 min at 4 C, and the
supernatant was collected, and protein was quantified using
the Qubit Protein Assay Kit and the Qubit 2.0 fluorometer
(Invitrogen). Twenty micrograms of protein extract was
loaded into a 12 % SDS–polyacrylamide gel in 19 Tris/
Glycine Buffer (BioRad). Magic Marker (Invitrogen) was
used as a protein standard. The gel electrophoresis rig was
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partially immersed in an ice bath while it ran for 1.5 h at
125 V. Proteins were transferred to a nitrocellulose mem-
brane using the iBlot system (Invitrogen) for 7 min at
20 V. The membranes were washed (19 PBS with 0.05 %
Tween 20) and incubated in blocking buffer for 60 min
(19 PBS with 0.05 % Tween 20 and 5 % w/v Instant
Nonfat Dry Milk). The membranes were then incubated
with primary antibody overnight at 4 C (19 PBS with
0.05 % Tween 20, 1 % w/v Instant Nonfat Dry Milk, and
500 ng/mL primary antibody) followed by three 10 min
washes (1x PBS with 0.05 % Tween 20). The following
primary antibodies from Santa Cruz Biotechnology were
used: CTSD sc-374381, and TNFRSF1A sc-8436. The
membrane was then incubated with secondary antibody
(19 PBS, 0.05 % Tween 20, 1 % Instant Nonfat Dry Milk,
and a 1:4,000 dilution of horseradish peroxidase (HRP)
conjugated goat anti-mouse secondary antibody (Thermo
Scientific)). The membrane was then washed (1x PBS with
0.05 % Tween 20) and incubated for 5 min in a substrate
solution of equal parts stable peroxide and luminol/
enhancer (SuperSignal West Femto Chemiluminescent
Substrate, Thermo Scientific). The membranes were then
imaged for chemiluminescence.
Small interfering RNA (siRNA) knockdown
We ordered two ON-TARGETplus custom siRNA duplex
reagents from Thermo Scientific that were designed to
target the fusion junctions of the read-through fusion
transcript and we also purchased ON-TARGETplus Non-
targeting siRNA #1 (Thermo Scientific catalog # #
D-001810-01-05), to serve as a control in our experi-
ments. To design our custom siRNAs, we first entered the
fusion junction nucleotide sequences into the siDESIGN
Center on the Thermo Scientific website. The software
was successfully designed CTSD-IFITM10 siRNA #1 to
the fusion junction. The software did not report any other
siRNAs. We then manually entered the fusion junction
sequence for CTSD-IFITM10 siRNA #2, so that we
would have a second siRNA targeting each fusion junc-
tion sequence with a more even representation of bases on








The siRNA transfection experiments were performed in
96-well plates in triplicate, and included a mock transfec-
tion control with no siRNA, a non-targeting siRNA control,
and the two custom siRNAs targeting the fusion junction.
The Lipofectamine RNAiMAX Transfection Reagent and
siRNA were prepared according the manufacturer’s
instructions (Invitrogen). We added 10 lL of the mix
containing siRNA and transfection reagent diluted in Opti-
MEM I Reduced Serum Medium (Invitrogen) to each well
in the 96-well plate containing cells, which results in
3 pmol of siRNA in 0.3 lL of Lipofectamine RNAiMAX
reagent per well.
Quantitative PCR (qPCR)
We ordered PCR primers flanking the fusion junction of
the CTSD-IFITM10 read-through fusion transcript, as well
as primers to the CTCF gene, which were used as a control








For siRNA experiments, we performed the qPCR assay
48 h after transfection. We prepared cDNA using the
Power SYBR Green Cells-to-CT Kit (Invitrogen) accord-
ing to the manufacturer’s instructions, including the option
of using 22.5 lL of cell lysate in the reverse transcription
reaction. For normal breast tissue experiments, we pre-
pared cDNA from 10 ng total RNA using the SuperScript
II (Invitrogen) Reverse Transcription Kit according to the
manufacturer’s instruction. Normal tissue cDNA was
diluted with 60 lL of water before qPCR.
qPCR experiments were run in duplicate in 10 lL reac-
tions with 4 lL of cDNA, 5 lL Power SYBR Green PCR
Master Mix, and PCR primers added to a final concentration
of 200 nM. For each cDNA sample, we also performed
control qPCR experiments using 400 nM of each primer
designed to CTCF, a housekeeping gene locus that we used
to ensure that the quantity and quality of cDNA were
equivalent across experiments. The reactions were run on an
ABI 7900HT with the following thermal cycling conditions:
50 C for 2 min, 95 C for 10 min, 40 cycles of 95 C for
15 s, and 60 C for 1 min. A dissociation curve analysis was
run using the standard protocol on the instrument. Transcript
abundance was calculated using automatic baseline and
threshold settings using the instrument’s software. To cal-
culate the percentage of transcript remaining after siRNA
knockdown, we first computed the fusion transcript delta
cycle threshold (dCt) by normalizing the fusion transcript
abundance measured in wells treated with siRNAs targeting
the fusion junction to the transcript abundance measured in
wells treated with the non-targeting siRNA. We then
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calculated the dCt values of the CTCF housekeeping control
locus from the same samples. We subtracted the CTCF dCt
from the fusion transcript dCt to compute the ddCt values
and compute the fold change of the fusion transcript
expression. As an additional control, we also performed this
ddCt calculation on the mock transfection with no siRNA to
ensure that the presence of the non-targeting siRNA did not
affect the abundance of the fusion transcript.
Cell proliferation
We performed cell proliferation assays 72 h after trans-
fection using the CyQUANT Cell Proliferation Assay Kit
for Cells in Culture (Invitrogen) according to the manu-
facturer‘s instruction. Our protocol included using 1.59
CyQUANT GR dye, which was recommended to obtain
adequate dynamic range in wells with 75,000 cells. The
fluorescence from each well of the 96-well plate was
measured using the Molecular Devices SpectraMax M5e
plate reader. To calculate the percentage of live cells
remaining after siRNA knockdown, we normalized the
fluorescence intensity in wells treated with siRNAs target-
ing the fusion junction to the fluorescence measured in
wells treated with the non-targeting siRNA. As a control,
we also performed this normalization on the mock trans-
fection with no siRNA to ensure that the presence of the
non-targeting siRNA did not affect the fluorescence or
quantity of live of the cells.
Data access
All RNA-seq data generated in this study are available for
download from the NCBI Gene Expression Omnibus
(GEO) (http://www.ncbi.nlm.nih.gov/geo/) through acces-
sion number GSE58135.
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